NVNO
enVVeno Medical Corp
NASDAQ · Healthcare · Medical - Devices · US
$6.91
−3.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 227.0K | — | 528.0K | 546.0K | 525.0K |
| Gross Profit | (227.0K) | — | (528.0K) | (546.0K) | (525.0K) |
| Operating Expenses | |||||
| R&D Expense | 9.0M | 10.0M | 12.2M | 13.6M | 9.9M |
| SG&A Expense | 7.3M | 10.9M | 11.0M | 11.1M | 14.5M |
| General & Admin Expense | 1.7M | 10.9M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (110.0K) | — | — | — | — |
| Total Operating Expenses | 16.2M | 20.9M | 23.3M | 24.7M | 24.4M |
| Cost and Expenses | 16.4M | 20.9M | 23.8M | 25.2M | 24.9M |
| Operating Income (EBIT) | (16.4M) | (20.9M) | (23.8M) | (25.2M) | (24.9M) |
| Non-Operating | |||||
| Interest Income | 150.0K | 692.0K | 389.0K | 180.0K | 161.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 150.0K | 692.0K | 389.0K | 180.0K | 161.0K |
| Other Non-Op Income/Expense | 853.0K | 1.4M | 2.0M | 1.7M | 263.0K |
| Non-Operating Income (excl Interest) | (473.0K) | (1.4M) | (2.0M) | (1.7M) | (263.0K) |
| EBT (Pre-Tax Income) | (15.6M) | (19.5M) | (21.8M) | (23.5M) | (24.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (15.6M) | (19.5M) | (21.8M) | (23.5M) | (24.7M) |
| Earnings from Cont. Ops | (15.6M) | (19.5M) | (21.8M) | (23.5M) | (24.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.6M) | (19.5M) | (21.8M) | (23.5M) | (24.7M) |
| Per Share | |||||
| Basic EPS | ($244.62) | ($33.06) | ($1,555.75) | ($2,339.75) | ($2,695.00) |
| Diluted EPS | ($244.62) | ($33.06) | ($1,555.75) | ($2,339.75) | ($2,695.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 694000 | 589000 | 13993 | 10042 | 9167 |
| Diluted Shares Outstanding | 694000 | 589000 | 13993 | 10042 | 9167 |
| Profitability Metrics | |||||
| EBITDA | (15.6M) | (19.0M) | (21.3M) | (23.0M) | (24.1M) |
| D&A | 380.0K | 489.0K | 528.0K | 546.0K | 525.0K |
| EBIT | (15.9M) | (19.5M) | (21.8M) | (23.5M) | (24.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026